Translated title of the contribution: Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials

José Silva-Cardoso, Omar Sheikh, Mouhamed Nashawi, Son Pham, Kelly M. Gallegos, Laith R. Dinkha, Robert J. Chilton

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors: noncardiovascular effects, cardiovascular benefits, and novel clinical indications. Multiple clinical trials and preliminary studies across varying disciplines have shown that these agents exhibit cardiorenal-protective benefits, retinoprotective benefits, and may aid in weight loss without causing marked hypoglycemia. Therefore, these agents represent an avenue in clinical practice to manage comorbid conditions in the hyperglycemic patient. Because of their multifaceted effects and robust action, SGLT2 inhibitors represent therapy options for providers that not only provide beneficial clinical results but also reduce total patient drug burden.

Translated title of the contributionCardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
Original languageChinese (Traditional)
Pages (from-to)279-293
Number of pages15
JournalJournal of Diabetes
Issue number4
StatePublished - Apr 1 2020


  • SGLT2 inhibitors
  • diabetic nephropathy
  • heart failure
  • macrovascular
  • microvascular
  • retinopathy
  • translational biology

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials'. Together they form a unique fingerprint.

Cite this